anti-inflammatory therapies for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
COLCHIVID NCT04367168		RCT	colchicine	placebo	COVID-19 severe or critically	NA	66/60	inconclusive	inconclusive 17 % decrease in death or transfer to ICU (PE)
Shi NCT04288102		RCT	stem cells	placebo	COVID-19 severe or critically	some concern	66/35	inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis